GP2015: An Etanercept Biosimilar (vol 31, pg 555, 2018)

被引：0

作者：

Deeks, Emma D. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

BIODRUGS | 2018年 / 32卷 / 05期

关键词：

D O I：

10.1007/s40259-018-0296-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The article GP2015: An Etanercept Biosimilar, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 31, issue 6, pages 555-558 HEXAL AG requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by HEXAL AG. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

引用

页码：525 / 525

页数：1

共 50 条

[1] GP2015: An Etanercept Biosimilar
Emma D. Deeks
[J]. BioDrugs, 2017, 31 : 555 - 558
[2] GP2015: An Etanercept Biosimilar
Deeks, Emma D.
[J]. BIODRUGS, 2017, 31 (06) : 555 - 558
[3] Correction to: GP2015: An Etanercept Biosimilar
Emma D. Deeks
[J]. BioDrugs, 2018, 32 (5) : 525 - 525
[4] A TOTALITY-OF-THE-EVIDENCE APPROACH TO THE DEVELOPMENT OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR
McCamish, M.
DaSilva, A.
Mayer, R. Ernst
Fritsch, C.
Schiestl, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1010 - 1010
[5] Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®)
Hofmann, Hans-Peter
Kronthaler, Ulrich
Fritsch, Cornelius
Grau, Roger
Mueller, Stefan O.
Mayer, Robert
Seidl, Andreas
Da Silva, Antonio
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (10) : 1185 - 1195
[6] The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar
Strand, Vibeke
Girolomoni, Giampiero
Schiestl, Martin
Mayer, Robert Ernst
Friccius-Quecke, Hilke
McCamish, Mark
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (06) : 993 - 1003
[7] NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES
Colaci, M.
Aprile, M. L.
La Rosa, A.
Di Maggio, A.
Malatino, L.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1135
[8] Effectiveness and safety of biosimilar etanercept GP2015 in patients with rheumatoid arthritis in the UK: results from the COMPACT study
Askari, Ayman
Both, Charlotte
Martin, Angela
Walsh, David A.
Sheeran, Tom
[J]. RHEUMATOLOGY, 2024, 63
[9] State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015
Poetzl, J.
Arlt, I.
von Richter, O.
Woehling, H.
Afonso, M.
Schaffar, G.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (04) : E130 - E132
[10] PHARMACOKINETICS AND SAFETY OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR, ADMINISTERED SUBCUTANEOUSLY BY AN AUTOINJECTOR OR PREFILLED SYRINGE IN HEALTHY MALE SUBJECTS
Afonso, M.
Kollins, D.
Macke, L.
Woehling, H.
Wuerth, G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 233 - 234

← 1 2 3 4 5 →